NCT04575961: PERCEPTION

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Active, enrolled Phase 2 Last updated 23 May 2025

What this trial tests

Phase 2 trial testing Pembrolizumab in Ovarian Cancer in 33 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 February 2022

Primary endpoint
1 March 2026

1 March 2028

Quick facts

Lead sponsor	North Eastern German Society of Gynaecological Oncology
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	22 February 2022
Primary completion	1 March 2026
Estimated completion	1 March 2028
Sites	2 locations across Germany

Drugs / interventions tested

• Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

• Ovarian Cancer — all drugs for Ovarian Cancer →
• Low Grade Serous Carcinoma — all drugs for Low Grade Serous Carcinoma →
• Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →
• Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →

Sponsor

North Eastern German Society of Gynaecological Oncology

Who can join

18 and older, female only, with Ovarian Cancer or Low Grade Serous Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin) administered concurrent to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma) having platinum-sensitive relapse (platinum-free interval \> 6 months).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
   Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. · · 2021 · cited 60× · PMID 34503248 · DOI 10.3390/cancers13174438
2. Low-grade serous ovarian cancer: expert consensus report on the state of the science.
   Grisham RN, Slomovitz BM, Andrews N, Banerjee S, et al · · 2023 · cited 50× · PMID 37591609 · DOI 10.1136/ijgc-2023-004610
3. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
   Pawłowska A, Rekowska A, Kuryło W, Pańczyszyn A, et al · · 2023 · cited 41× · PMID 37446039 · DOI 10.3390/ijms241310859
4. Low-Grade Serous Carcinoma of the Ovary: The Current Status.
   Babaier A, Mal H, Alselwi W, Ghatage P. · · 2022 · cited 36× · PMID 35204549 · DOI 10.3390/diagnostics12020458
5. Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer.
   Huang X, Li XY, Shan WL, Chen Y, et al · · 2023 · cited 14× · PMID 37033645 · DOI 10.3389/fphar.2023.1131342
6. Targeted Therapies in Low-Grade Serous Ovarian Cancers.
   Gonzalez A, Nagel CI, Haight PJ. · · 2024 · cited 8× · PMID 38869696 · DOI 10.1007/s11864-024-01205-4
7. Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
   Onoprienko A, Bartl T, Grimm C, Concin N, et al · · 2024 · cited 4× · PMID 39409889 · DOI 10.3390/cancers16193268
8. Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review.
   Giannecchini GV, da Silva JL, de Oliveira Bretas G, Dos Santos ALS, et al · · 2024 · cited 1× · PMID 38835797 · DOI 10.3389/fmed.2024.1366603